<?xml version='1.0' encoding='utf-8'?>
<document id="29345798"><sentence text="Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications." /><sentence text="Direct-acting antiviral agents (DAAs) for the treatment of hepatitis C (HCV) can be associated with drug-drug interactions (DDIs) with concomitant medications" /><sentence text=" The practical clinical implications of such DDIs are poorly understood" /><sentence text=" We assessed the clinical impact of possible pharmacokinetic (PK) interactions between simeprevir and frequently prescribed concomitant medications" /><sentence text="" /><sentence text="This post hoc analysis pooled data from nine studies which evaluated simeprevir (SMV)-based interferon-free HCV treatment"><entity charOffset="69-79" id="DDI-PubMed.29345798.s6.e0" text="simeprevir" /></sentence><sentence text=" Three classes of frequently used concomitant medications of interest (CMOIs) were analysed [antihypertensive drugs (AHDs), anxiolytic drugs (AXDs) and lipid-lowering drugs (LLDs)] and categorized as amber or green according to their DDI potential with SMV (green: no DDIs; amber: potential/known PK interactions)" /><sentence text=" Concomitant medications not recommended to be coadministered with SMV were not included" /><sentence text=" The composite primary endpoint was defined as the frequency of either discontinuation, interruption or dose modification of the CMOI during 12Â weeks of SMV treatment" /><sentence text="" /><sentence text="Few patients met the composite endpoint in the various subgroups" /><sentence text=" Patients on amber CMOIs tended to experience CMOI modification more often (13" /><sentence text="4-19" /><sentence text="4%) than those on green CMOIs (3" /><sentence text="1-10" /><sentence text="8%)" /><sentence text=" There was no difference in the frequency of adverse events between patients taking green and those taking amber CMOIs" /><sentence text="" /><sentence text="In this large pooled analysis, coadministration of the evaluated commonly prescribed medications with known or potential PK interactions with SMV was manageable and resulted in few adjustments of concomitant medications" /><sentence text=" Our method could serve as a blueprint for the evaluation of the impact of DDIs" /><sentence text="" /></document>